郭炳辰,唐昊,李光辉,段宇辰,涂应锋

• 1:哈尔滨医科大学附属第一医院心血管内科

摘要(Abstract)：

心力衰竭是大多数心血管疾病的终末期表现，在全球范围内，心力衰竭的负担已增加到约6 400多万人。这些心力衰竭患者在基础药物治疗之后逐步改善预后和生活质量，但由于心力衰竭的复杂性和多样性，与多种危险因素、症状和并发症相关，以及尚未完全了解的病理生理机制，心力衰竭仍具有很高的发病率、住院率和死亡率。近几年来，慢性心力衰竭神经调节治疗技术取得了重大突破，用于治疗自主神经调节功能紊乱和心电活动异常的各种治疗技术正在慢性心力衰竭患者中进行研究。神经调节治疗技术主要用于改善机械不同步和自主神经失衡的电刺激和神经调节两个方面，这些技术包括经导管去肾交感神经术、内脏大神经消融术、迷走神经刺激术、肺动脉去神经术和心脏收缩调节器。本文旨在讨论目前慢性心力衰竭神经调节治疗技术的应用与研究进展。

关键词(KeyWords)： 心力衰竭;神经调节治疗;经导管去肾交感神经术;内脏大神经消融术;迷走神经刺激术;肺动脉去神经术;心脏收缩调节器

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 郭炳辰,唐昊,李光辉,段宇辰,涂应锋

参考文献(References)：

• [1]廖建泉，葛均波.去肾交感神经在心血管疾病应用中的研究进展[J].中国介入心脏病学杂志，2015,23(9):512-515.DOI:10.3969/j.issn.1004-8812.2015.09.008.
• [2] Sharp TE,Lefer DJ. Renal denervation to treat heart failure[J].Annu Rev Physiol, 2021,83:39-58. DOI:10.1146/annurevphysiol-031620-093431.
• [3] Heidenreich PA,Bozkurt B,Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation,2022,145(18):e876-e894.DOI:10.1161/CIR.0000000000001062.
• [4] Kassab K,Soni R,Kassier A, et al. The potential role of renal denervation in the management of heart failure[J]. J Clin Med,2022,11(14):4147. DOI:10.3390/jcm11144147.
• [5] Chen P,Guo Z,Chen Y, et al. The infl uence of inhibiting renal neural regeneration on the e fficacy of renal denervation to chronic heart failure[J]. ESC Heart Fail,2021,8(6):4760-4771.DOI:10.1002/ehf2.13655.
• [6] Gao JQ,Yang W,Liu ZJ. Percutaneous renal artery denervation in patients with chronic systolic heart failure:a randomized controlled trial[J]. Cardiol J,2019,26(5):503-510.DOI:10.5603/CJ.a2018.0028.
• [7] Li M,Ma W,Fan F, et al. Renal denervation in management of heart failure with reduced ejection fraction:a systematic review and Meta-analysis[J]. J Cardiol,2023,81(6):513-521. DOI:10.1016/j.jjcc.2023.01.010.
• [8] Kresoja KP,Rommel KP,Fengler K, et al. Renal sympathetic denervation in patients with heart failure with preserved ejection fraction[J]. Circ Heart Fail,2021,14(3):null. DOI:10.1161/CIRCHEARTFAILURE.120.007421.
• [9] Mahfoud F,Urban D,Teller D, et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension:data from a multi-centre cardiovascular magnetic resonance imaging trial[J]. Eur Heart J,2014,35(33):2224-31b. DOI:10.1093/eurheartj/ehu093.
• [10] Fudim M,Sobotka PA,Piccini JP, et al. Renal denervation for patients with heart failure:making a full circle[J].Circ Heart Fail, 2021,14(3):e008301. DOI:10.1161/CIRCHEARTFAILURE.121.008301.
• [11] Yamada S,Lo LW,Chou YH, et al. Renal denervation ameliorates the risk of ventricular fi brillation in overweight and heart failure[J]. Europace,2020,22(4):657-666. DOI:10.1093/europace/euz335.
• [12] Hawson J,Harmer JA,Cowan M, et al. Renal denervation for the management of refractory ventricular arrhythmias:a systematic review[J]. JACC Clin Electrophysiol,2021,7(1):100-108. DOI:10.1016/j.jacep.2020.07.019.
• [13] Málek F,Gajewski P,Zymliński R, et al. Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserve d ejection fraction：fi rst-in-human clinical trial[J].Eur J Heart Fail,2021,23(7):1134-1143. DOI:10.1002/ejhf.2209.
• [14] Fudim M,Fail PS,Litwin SE, et al. Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction:early results of the REBALANCE-HF trial roll-in cohort[J]. Eur J Heart Fail,2022,24(8):1410-1414. DOI:10.1002/ejhf.2559.
• [15] Gajewski P,Fudim M,Kittipibul V, et al. Early hemodynamic changes following surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction[J]. J Clin Med,2022,11(4):1063. DOI:10.3390/jcm11041063.
• [16] Fudim M,Zirakashvili T,Shaburishvili N, et al. Transvenous right greater splanchnic nerve ablation in heart failure and preserved ejection fraction:first-in-human study[J]. JACC Heart Fail,2022,10(10):744-752. DOI:10.1016/j.jchf.2022.05.009.
• [17] Fudim M,Boortz-Marx RL,Ganesh A, et al. Splanchnic nerve block for chronic heart failure[J]. JACC Heart Fail,2020,8(9):742-752. DOI:10.1016/j.jchf.2020.04.010.
• [18] Fudim M,Engelman ZJ,Reddy VY, et al. Splanchnic nerve ablation for volume management in heart failure[J]. JACC Basic Transl Sci,2022,7(3):319-321. DOI:10.1016/j.jacbts.2022.02.005.
• [19] Xue N,Martinez ID,Sun J, et al. Flexible multichannel vagus nerve electrode for stimulation and recording for heart failure treatment[J]. Biosens Bioelectron,2018,112:114-119.DOI:10.1016/j.bios.2018.04.043.
• [20] Gold MR,Van Veldhuisen DJ,Hauptman PJ,et al.Vagus nerve stimulation for the treatment of heart failure:the INOVATE-HF trial[J]. J Am Coll Cardiol,2016,68(2):149-158. DOI:10.1016/j.jacc.2016.03.525.
• [21] Babar N,Giedrimiene D. Updates on baroreflex activation therapy and vagus nerve stimulation for treatment of heart failure with reduced ejection fraction[J]. Cardiol Res,2022,13(1):11-17. DOI:10.14740/cr1330.
• [22] Nagai M,Dote K,Kato M, et al. Afterload reduction after non-invasive vagus nerve stimulation in acute heart failure[J].Front Hum Neurosci,2023,17:1149449. DOI:10.3389/fnhum.2023.1149449.
• [23] Sharma K,Premchand RK,Mittal S, et al. Long-term followup of patients with heart failure and reduced ejection fraction receiving autonomic regulation therapy in the ANTHEM-HF pilot study[J]. Int J Cardiol,2021,323:175-178. DOI:10.1016/j.ijcard.2020.09.072.
• [24] Kumar HU,Nearing BD,Mittal S, et al. Autonomic regulation therapy in chronic heart failure with preserved/mildly reduced ejection fraction:ANTHEM-HFpEF study results[J]. Int J Cardiol,2023,381:37-44. DOI:10.1016/j.ijcard.2023.03.030.
• [25] Elkholey K,Niewiadomska M,Morris L, et al. Transcutaneous vagus nerve stimulation ameliorates the phenotype of heart failure with preserved ejection fraction through its anti-inflammatory ef fects[J]. Circ Heart Fail,2022,15(8):e009288. DOI:10.1161/CIRCHEARTFAILURE.122.009288.
• [26] Stavrakis S,Elkholey K,Morris L, et al. Neuromodulation of inflammation to treat heart failure with preserved ejection fraction:a pilot randomized clinical trial[J]. J Am Heart Assoc,2022,11(3):e023582. DOI:10.1161/JAHA.121.023582.
• [27] Verrier RL,Libbus I,Nearing BD, et al. Multifactorial benefi ts of chronic vagus nerve stimulation on autonomic function and cardiac electrical stability in heart failure patients with reduced ejection fraction[J]. Front Physiol,2022,13:855756.DOI:10.3389/fphys.2022.855756.
• [28] Xiao M,Lai D,Yu Y, et al. Pathogenesis of pulmonary hypertension caused by left heart disease[J]. Front Cardiovasc Med,2023,10:1079142. DOI:10.3389/fcvm.2023.1079142.
• [29] Al-Omary MS,Sugito S,Boyle AJ, et al. Pulmonary hypertension due to left heart disease:diagnosis, pathophysiology, and therapy[J]. Hypertension,2020,75(6):1397-1408. DOI:10.1161/HYPERTENSIONAHA.119.14330.
• [30]高强，徐巍，王定宇，等.肺动脉高压介入治疗研究进展[J].中国介入心脏病学杂志，2020,28(11):644-646.DOI:10.3969/j.issn.1004-8812.2020.11.009.
• [31] Maron BA,Kovacs G,Vaidya A, et al. Cardiopulmonary hemodynamics in pulmonary hypertension and heart failure:JACC review topic of the week[J]. J Am Coll Cardiol,2020,76(22):2671-2681. DOI:10.1016/j.jacc.2020.10.007.
• [32] Davies MG,Miserlis D,Hart JP. Current status of pulmonary artery denervation[J]. Front Cardiovasc Med,2022,9:972256. DOI:10.3389/fcvm.2022.972256.
• [33] Zheng Z,Chen R,Sun X, et al. A Meta-analysis of the e fficacy of pulmonary artery denervation in the treatment of pulmonary hypertension[J]. Heart Lung,2022,53:42-50. DOI:10.1016/j.hrtlng.2022.01.020.
• [34] Zhong L,Leng S,Alabed S, et al. Pulmonary artery strain predicts prognosis in pulmonary arterial hypertension[J]. JACC Cardiovasc Imaging,2023,16(8):1022-1034. DOI:10.1016/j.jcmg.2023.02.007.
• [35] Zhang H,Wei Y,Zhang C,et al. Pulmonary artery denervation for pulmonary arterial hypertension:a Sham-controlled randomized PADN-CFDA trial[J]. JACC Cardiovasc Interv,2022,15(23):2412-2423. DOI:10.1016/j.jcin.2022.09.013.
• [36] Z h a n g H, Z h a n g J, C h e n M, e t a l. P u l m o n a r y a r t e r y denervation significantly increases 6-min walk distance for patients with combined pre-and post-capillary pulmonary hypertension associated with left heart failure:the PADN-5study[J]. JACC Cardiovasc Interv,2019,12(3):274-284. DOI:10.1016/j.jcin.2018.09.021.
• [37] Witkowski A,Szumowski?，Urbanek P, et al. Transcatheter pulmonary denervation in patients with left heart failure with reduced ejection fraction and combined precapillary and postcapillary pulmonary hypertension:a prospective single center experience[J]. Catheter Cardiovasc Interv,2021,98(3):588-594. DOI:10.1002/ccd.29526.
• [38] Kim CW,Aronow WS,Dutta T, et al. Pulmonary artery denervation as an innovative treatment for pulmonary hypertension with and without heart failure[J]. Cardiol Rev,2021,29(2):89-95. DOI:10.1097/CRD.0000000000000299.
• [39] Romanov A,Cherniavskiy A,Novikova N, et al. Pulmonary artery denervation for patients with residual pulmonary hypertension after pulmonary endarterectomy[J]. J Am Coll Cardiol,2020,76(8):916-926. DOI:10.1016/j.jacc.2020.06.064.
• [40] Chinyere IR,Balakrishnan M,Hutchinson MD. The emerging role of cardiac contractility modulation in heart failure treatment[J].Curr Opin Cardiol, 2022,37(1):30-35. DOI:10.1097/HCO.0000000000000929.
• [41] Wiegn P,Chan R,Jost C, et al. Safety, Performance,and e fficacy of cardiac contractility modulation delivered by the2-lead Optimizer smart system:the FIX-HF-5C2 study[J].Circ Heart Fail,2020,13(4):e006512. DOI:10.1161/CIRCHEARTFAILURE.119.006512
• [42] Tint D,Micu S. One-year outcome of cardiac contractility modulation in patients with reduced ejection fraction, atrial fibrillation, and previous resynchronization:a pilot study[J]. Am J Ther,2023,30(1):e10-e16. DOI:10.1097/MJT.0000000000001579.
• [43] Linde C,Grabowski M,Ponikowski P, et al. Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction:a pilot study(CCM-HFpEF)[J]. Eur J Heart Fail,2022,24(12):2275-2284. DOI:10.1002/ejhf.2619.
• [44] Fastner C,Yuecel G,Hetjens S, et al. Should HFrEF patients with NYHA classⅡexpect benefi t from CCM therapy? Results from the MAINTAINED observational study[J]. Clin Res Cardiol,2022,111(11):1286-1294. DOI:10.1007/s00392-022-02089-w.
• [45] Talha KM,Anker SD,Burkhoff D, et al. Role of cardiac contractility modulation in heart failure with a higher ejection fraction[J]. J Card Fail,2022,28(12):1717-1726.DOI:10.1016/j.cardfail.2022.08.013.
• [46]左海润，徐承义，苏晞.第五代心肌收缩力调节器在慢性心力衰竭患者中的应用4例[J].中国介入心脏病学杂志，2022,30(11):833-838. DOI:10.3969/j.issn.1004-8812.2022.11.006.